查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
2012790

抗凝血酶市场：按类型、原料、剂型、剂量形式、治疗应用和最终用户划分－2026-2032年全球市场预测

Antithrombin Market by Type, Source, Form, Dosage Form, Therapeutic Application, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 192 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，抗凝血酶市场价值将达到 7.8032 亿美元，到 2026 年将成长至 8.1865 亿美元，到 2032 年将达到 10.9515 亿美元，年复合成长率为 4.96%。

主要市场统计数据
基准年 2025 780,320,000 美元
预计年份：2026年 8.1865亿美元
预测年份 2032 1,095,150,000 美元
复合年增长率 (%) 4.96%

全面介绍了抗凝血酶的生物学、临床意义、诊断复杂性和治疗意义，它塑造了现代凝血医学。

抗凝血酶是丝胺酸蛋白酶抑制剂，可调节凝血酶和因子Xa的活性，在止血过程中发挥核心作用，其临床和研究价值在近几十年显着提升。临床医生面临频谱抗凝血酶缺乏症，从遗传性终身疾病到与严重相关的后天性缺乏症，这些都影响着治疗决策和风险管理策略。从转化科学的角度来看，抗凝血酶作为生物标记和治疗候选药物都发挥着至关重要的作用，而血浆来源和重组来源的差异会影响其安全性、免疫抗原性和生产过程等方面的考量。

科学、监管和临床趋势正在改变抗凝血酶疗法的开发、诊断方法和医疗保健服务模式。

由于科学进步、监管压力和临床实践的不断发展，抗凝血酶领域正经历着变革性的变化。重组技术的创新正在减少对血浆来源原料的依赖，引发了更多关于生产规模化、产品均一性和批间差异的讨论。同时，检测准确性的提高和照护现场诊断技术的进步使得早期准确识别抗凝血酶缺乏症成为可能，从而影响着预防策略和高风险环境下的急性期治疗管理。

评估 2025 年美国关税措施如何重塑抗凝血酶供应链的供应链、采购重点和国内生产策略。

美国2025年实施的关税政策为抗凝血酶生态系统增添了新的复杂性，影响整个价值链的筹资策略和供应商选择。进口关税正在影响製造商在本地化生产、填充和包装业务伙伴关係以及供应链路线选择方面的决策，以降低不断上涨的接收成本。为此，医院和大规模综合医疗网络正在审查供应商合同，并优先考虑多元化和紧急储备，以维持临床服务的连续性。

将产品异构体、采购途径、配方选择、治疗应用和最终用户需求与临床引入和开发重点联繫起来的详细细分见解。

基于细分市场的分析揭示了不同产品类型和终端使用者因素如何影响抗凝血酶的临床效用、开发选择和部署动态。按类型分析，α和β异构体由于其不同的生化特性和生理功能，会影响诊断解读和治疗靶点，进而可能影响检测方法的选择和个体化治疗。依来源分析，人类血浆来源抗凝血酶与重组抗凝血酶的比较凸显了供体依赖性、病原体安全性以及生产控制方面的权衡取舍，这些因素常常与医疗采购政策和临床医生的偏好交织在一起。

从全面的区域观点解释美洲、欧洲、中东和非洲以及亚太地区的趋势如何影响抗凝血酶的生产、监管和临床应用。

区域趋势对抗凝血酶的生产、监管和应用有显着影响，因此，了解地理差异对于策略规划至关重要。在美洲，临床网路和医院系统优先考虑快速获得急性护理，并维持复杂的采购流程以平衡价格和供应连续性，而区域法规结构强调供体安全和生物製药可追溯性。在欧洲、中东和非洲地区，监管差异和医疗基础设施的多样性导致了广泛的取得和应用模式。有些市场倾向于集中采购，而有些市场则依赖区域伙伴关係进行供应和低温运输物流管理。

本报告从公司层面深入分析了製造商、生物技术创新者和专家合作伙伴如何透过製造、监管策略和临床合作实现差异化。

抗凝血酶领域的竞争格局和合作框架涵盖了成熟的生技药品企业、新兴生物技术公司以及专业的合约研发生产机构（CDMO），每家企业都拥有独特的优势。有些公司专注于血浆衍生产品的专业知识和供体安全体系，而有些公司则大力投资于重组表达平台和製程改进技术，以提高产量并降低变异性。临床研究团队与生产者之间的策略合作日益普遍，有助于快速获得新适应症的证据，并改善上市后监测。

为高阶主管提供切实可行的建议，以加强整个抗凝血酶价值链的生产韧性、监管合作和临床导入策略。

行业领导者应采取一系列切实有效的措施，以应对科学进步、政策转变和不断变化的临床需求。首先，他们应投资于灵活的生产策略，将重组生产能力与地理分散的填充和包装能力结合，以减少对单一供应商的依赖，并满足区域采购需求。其次，他们应优先考虑对可靠的分析方法和检测手段进行外部检验，以提高诊断可靠性，并支持其在不同医疗环境中的临床应用。第三，他们应积极与监管机构合作，就可追溯性、病原体安全措施以及上市后证据的建立达成共识，从而促进产品接受度和长期安全性监测。

该文件清楚地解释了一种混合方法研究途径，该方法整合了文献分析、监管审查、技术评估和专家访谈，有助于实际决策。

本分析整合了来自同行评审文献、监管文件、临床试验註册资讯、产品标籤、生产白皮书以及与临床医生、供应链专家和行业专业人士的结构化访谈的证据。关键的定性资讯与实验室审查和配方材料进行了交叉核对，以确保对产品特性和临床工作流程的全面了解。透过对调查方法研究应用标准化评估标准、交叉参考主要司法管辖区的监管指南以及记录每项关键声明的资料来源，确保了方法论的严谨性。

结论：整合突显了科学创新、营运韧性和策略参与之间的相互作用，这对于推进抗凝血酵素科学和促进临床应用至关重要。

总之，抗凝血酶是一个涉及多方面的临床和技术领域，科学细节、生产选择和医疗服务现实相互交织。重组技术、诊断准确性和区域生产投资的持续进步正在改变产品的开发、监管和消费方式。贸易政策趋势凸显了供应链韧性和本地生产能力的重要性，而按异构体、原材料、剂型、给药途径、治疗用途和最终用户背景进行的细分则强调了製定精心定制的产品和商业化策略的必要性。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席体验长观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章：抗凝血酶市场：按类型划分

  • 阿尔法
  • 测试版

第九章：抗凝血酶市场：依来源划分

  • 人类血浆
  • 重组

第十章：抗凝血酶市场：依剂型划分

  • 液体
  • 粉末

第十一章 以剂型分類的抗凝血酶市场

  • 注射药物
  • 口服悬浮液

第十二章：依治疗应用分類的抗凝血酶市场

  • 后天性缺陷
  • 急性胰臟炎
  • 先天性缺陷
  • 瀰漫性血管内凝血
  • 肝病
  • 败血症相关凝血障碍

第十三章：抗凝血酶市场：依最终用户划分

  • 门诊手术中心
  • 诊所
  • 诊断检查室
  • 医院
  • 研究机构

第十四章：抗凝血酶市场：依地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十五章：抗凝血酶市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十六章 抗凝血酶市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十七章：美国抗凝血酶市场

第十八章：中国抗凝血酶市场

第十九章 竞争情势

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Baxter International Inc.
  • Bio-Techne Corporation
  • Biocon Ltd.
  • Boehringer Ingelheim Pharma GmbH & Co. KG
  • China Biologic Products, Inc.
  • Diapharma Group, Inc.
  • European Medicines Agency
  • F. Hoffmann-La Roche Ltd
  • Genesis BioPharma Services
  • Grifols, SA
  • Jiangsu Hengrui Medicine Co., Ltd.
  • Lee Biosolutions, Inc.
  • LFB USA, Inc.
  • Merck KGaA
  • Novartis AG
  • Octapharma AG
  • Pfizer Inc.
Product Code: MRR-4358BACA8223

The Antithrombin Market was valued at USD 780.32 million in 2025 and is projected to grow to USD 818.65 million in 2026, with a CAGR of 4.96%, reaching USD 1,095.15 million by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 780.32 million
Estimated Year [2026] USD 818.65 million
Forecast Year [2032] USD 1,095.15 million
CAGR (%) 4.96%

Comprehensive introduction to antithrombin biology, clinical relevance, diagnostic complexity, and therapeutic implications shaping contemporary coagulation care

Antithrombin occupies a central role in hemostasis as a serine protease inhibitor that modulates thrombin and factor Xa activity, and its clinical and research significance has expanded markedly over recent decades. Clinicians encounter antithrombin deficiency across a spectrum that ranges from inherited, lifelong disorders to acquired deficiencies in critical illness, which in turn influence therapeutic decision-making and risk management strategies. From a translational science perspective, antithrombin is consequential both as a biomarker and as a therapeutic agent candidate, with distinctions between plasma-derived and recombinant sources shaping safety, immunogenicity, and manufacturing considerations.

As regulatory frameworks evolve, diagnostic algorithms increasingly integrate antithrombin activity assays with genetic and clinical data to refine case definitions and guide replacement therapy. Furthermore, advances in formulation science and delivery modalities have begun to change how antithrombin products are stored, administered, and integrated into acute and chronic care pathways. Taken together, these elements establish antithrombin as a nexus point between laboratory investigation, bedside practice, and therapeutic innovation, with downstream implications for hospitals, diagnostic laboratories, and research programs seeking to optimize patient outcomes.

Evolving scientific, regulatory, and clinical dynamics that are transforming antithrombin product development, diagnostic approaches, and care delivery models

The landscape surrounding antithrombin is undergoing transformative shifts driven by scientific progress, regulatory pressure, and evolving clinical practice. Innovations in recombinant technology have reduced reliance on plasma-derived sources and have catalyzed discussions about manufacturing scalability, product consistency, and batch-to-batch variability. Concurrently, improvements in assay precision and point-of-care diagnostics are enabling earlier and more accurate identification of antithrombin insufficiency, which affects both prophylactic strategies and acute management in high-risk settings.

In parallel, therapeutic paradigms are being reshaped by a clearer understanding of antithrombin's role in inflammation and endothelial biology, prompting investigation into broader indications beyond classical coagulation disorders. Regulatory scrutiny related to plasma sourcing and pathogen inactivation methods has raised expectations for traceability and safety, while health systems emphasize supply chain resilience and cold chain optimization. As a result, stakeholders across production, clinical, and institutional domains are recalibrating priorities to balance efficacy, safety, and operational feasibility, and these shifts will influence procurement, clinical guidelines, and R&D roadmaps going forward.

Assessment of how the 2025 United States tariff measures recalibrated supply chains, procurement priorities, and domestic production strategies in the antithrombin supply network

United States tariff policies implemented in 2025 have introduced a new layer of complexity for the antithrombin ecosystem, affecting procurement strategies and supplier selection across the value chain. The import tariffs have influenced manufacturer decisions regarding localization of production, partnerships for fill-and-finish operations, and supply chain routing to mitigate incremental landed costs. Hospitals and large integrated delivery networks have responded by revisiting supplier contracts, emphasizing multi-sourcing arrangements and contingency inventories to preserve clinical continuity.

In downstream terms, the tariffs have accelerated conversations about domestic capacity and the feasibility of scaling recombinant production within national borders. Simultaneously, diagnostic laboratories and research institutes have weighed the operational trade-offs associated with alternative sourcing, including increased lead times and the potential need for cold chain redundancies. Although procurement teams navigated near-term administrative burdens, the policy environment also catalyzed strategic investments in local manufacturing partnerships and process optimization initiatives aimed at reducing exposure to future external policy shifts. Looking ahead, stakeholders are increasingly prioritizing resilience, transparency, and adaptive supply frameworks to manage the ripple effects of trade policy on antithrombin accessibility and reliability.

Detailed segmentation insights linking product isoforms, sourcing routes, formulation choices, therapeutic uses, and end-user needs to clinical adoption and development priorities

Segmentation-driven analysis reveals how different product and end-user vectors shape clinical utility, development choices, and adoption dynamics for antithrombin. When examined by type, the distinctions between alpha and beta isoforms inform diagnostic interpretation and therapeutic targeting because biochemical properties and physiological roles vary, which can influence assay selection and treatment tailoring. By source, contrasts between human plasma-derived and recombinant antithrombin highlight trade-offs in donor-dependence, pathogen safety, and manufacturing control, and these factors frequently intersect with institutional procurement policies and clinician preferences.

Considering form factors, the distinctions between liquid and powder formulations matter for storage, shelf life, and reconstitution workflows in clinical settings, and these attributes determine how products are integrated into infusion suites and emergency protocols. Dosage form differentiation between injectable preparations and oral suspensions shapes administration pathways and patient adherence considerations, particularly in ambulatory care and home infusion contexts. Across therapeutic applications, antithrombin is applied in acquired deficiency, acute pancreatitis, congenital deficiency, disseminated intravascular coagulation, liver disease, and sepsis associated coagulopathy, each presenting unique clinical endpoints, monitoring demands, and evidence hierarchies. Finally, end-user segmentation encompassing ambulatory surgical centers, clinics, diagnostic laboratories, hospitals, and research institutes underscores that adoption drivers differ by care setting, with hospitals emphasizing acute use and intensive monitoring, diagnostic laboratories prioritizing assay reliability, and research institutes concentrating on mechanistic studies and translational validation.

Comprehensive regional perspective explaining how Americas, Europe Middle East & Africa, and Asia-Pacific trends influence production, regulation, and clinical access for antithrombin

Regional dynamics exert a powerful influence on how antithrombin is produced, regulated, and deployed, and understanding geographic nuances is essential for strategic planning. In the Americas, clinical networks and hospital systems often prioritize rapid access to acute care therapies and maintain complex procurement protocols that balance price with supply continuity, while regional regulatory frameworks emphasize donor safety and biologic traceability. In Europe, Middle East & Africa, regulatory heterogeneity and variable healthcare infrastructures create a spectrum of access and adoption patterns, with some markets emphasizing centralized procurement and others relying on local partnerships to manage supply and cold chain logistics.

Across the Asia-Pacific region, rising investment in biotechnology manufacturing capacity and growing clinical research activity are reshaping supplier footprints and increasing the availability of recombinant options. Transitional healthcare systems in multiple jurisdictions are also expanding diagnostic capabilities, which improves detection of antithrombin abnormalities and supports evidence generation for diverse therapeutic applications. Taken together, these geographic trends suggest that product strategy, regulatory engagement, and distribution models must be tailored to regional priorities, and that cross-border collaboration and technology transfer will remain important levers for improving availability and clinical outcomes globally.

Key company-level insights describing how manufacturers, biotech innovators, and specialized partners differentiate through manufacturing, regulatory strategy, and clinical collaboration

The competitive and collaborative landscape for antithrombin includes a mix of established biologics manufacturers, emerging biotechnology firms, and specialized contract development and manufacturing organizations, each contributing distinct capabilities. Some players emphasize plasma-derived expertise and donor-safety systems, while others have invested heavily in recombinant expression platforms and process intensification techniques to enhance yield and reduce variability. Strategic alliances between clinical research groups and manufacturers have become more prevalent, enabling accelerated evidence generation for novel indications and improved post-market surveillance frameworks.

In addition, partnerships with specialized logistics providers and diagnostic firms are helping to optimize cold chain integrity and assay standardization, which in turn supports safer and more reliable product deployment. Competitive differentiation increasingly rests on a combination of manufacturing robustness, regulatory lifecycle management, and the ability to supply comprehensive technical support to clinical customers. As stakeholders pursue broader clinical validation and potential label expansions, intellectual property strategies, platform technologies, and manufacturing footprint decisions will continue to shape which companies lead in innovation and where collaborative consortia may offer collective advantages.

Actionable recommendations for executives to enhance manufacturing resilience, regulatory engagement, and clinical adoption strategies across the antithrombin value chain

Industry leaders should adopt a set of pragmatic, high-impact actions to navigate scientific developments, policy shifts, and evolving clinical needs. First, invest in flexible manufacturing strategies that combine recombinant production capabilities with geographically distributed fill-and-finish capacity to reduce single-source exposure and to respond to regional procurement preferences. Second, prioritize robust analytical methods and external validation of assays to improve diagnostic confidence and to support clinical adoption across diverse care settings. Third, engage proactively with regulatory authorities to align on traceability, pathogen-safety approaches, and post-market evidence generation that will facilitate product acceptance and long-term safety monitoring.

Additionally, cultivate strategic partnerships with hospital systems, diagnostic laboratories, and research institutes to co-design real-world evidence generation efforts that demonstrate clinical value across the therapeutic applications where antithrombin may be impactful. Strengthen supply chain resiliency by diversifying logistics partners and investing in cold chain redundancy, while also exploring contract manufacturing relationships that can be scaled quickly in response to policy or demand shifts. Finally, enhance commercial readiness through targeted education for clinicians and procurement teams that clarifies product differentiators, administration workflows, and the implications of source and formulation choices for patient management.

Clear explanation of the mixed-methods research approach integrating literature synthesis, regulatory review, technical assessment, and expert interviews to inform practical decision-making

This analysis synthesizes evidence from peer-reviewed literature, regulatory documents, clinical trial registries, product labelling, manufacturing white papers, and structured interviews with clinicians, supply chain professionals, and industry experts. Primary qualitative inputs were triangulated with laboratory method reviews and formulation dossiers to ensure a comprehensive view of product characteristics and clinical workflows. Methodological rigor was maintained by applying standardized appraisal criteria to clinical studies, cross-referencing regulatory guidance across major jurisdictions, and documenting data provenance for each major assertion.

Where possible, technical assessments of recombinant versus plasma-derived production were corroborated with process descriptions and expert commentary on scalability and quality control. Supply chain and policy impacts were evaluated through scenario analysis and stakeholder interviews to capture operational realities and adaptive strategies. Throughout, the approach emphasized transparency, reproducibility, and practical relevance for decision-makers, and caveats were noted where evidence was evolving or where clinical consensus had not yet been established. This mixed-methods framework ensures that conclusions rest on multiple, corroborative lines of evidence and that recommendations are tailored to real-world operational constraints.

Concluding synthesis emphasizing the interplay of scientific innovation, operational resilience, and strategic engagement necessary to advance antithrombin science and clinical access

In conclusion, antithrombin represents a multifaceted clinical and technological domain where scientific nuance, production choices, and healthcare delivery realities intersect. Ongoing advances in recombinant technologies, diagnostic precision, and regional manufacturing investments are changing how products are developed, regulated, and consumed. Trade policy developments have underscored the importance of supply chain resilience and local capacity, while segmentation across isoform, source, form, dosage form, therapeutic application, and end-user context highlights the need for finely calibrated product and commercialization strategies.

To succeed in this environment, stakeholders must balance innovation with operational reliability, engage early with regulators and clinical opinion leaders, and align manufacturing footprints with regional access imperatives. By combining rigorous evidence generation, strategic partnerships, and adaptive logistics planning, organizations can position themselves to meet clinical demand effectively while also advancing the science of antithrombin therapeutics and diagnostics.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Antithrombin Market, by Type

  • 8.1. Alpha
  • 8.2. Beta

9. Antithrombin Market, by Source

  • 9.1. Human Plasma
  • 9.2. Recombinant

10. Antithrombin Market, by Form

  • 10.1. Liquid
  • 10.2. Powder

11. Antithrombin Market, by Dosage Form

  • 11.1. Injectable
  • 11.2. Oral Suspensions

12. Antithrombin Market, by Therapeutic Application

  • 12.1. Acquired Deficiency
  • 12.2. Acute Pancreatitis
  • 12.3. Congenital Deficiency
  • 12.4. Disseminated Intravascular Coagulation
  • 12.5. Liver Disease
  • 12.6. Sepsis Associated Coagulopathy

13. Antithrombin Market, by End User

  • 13.1. Ambulatory Surgical Centers
  • 13.2. Clinics
  • 13.3. Diagnostic Laboratories
  • 13.4. Hospitals
  • 13.5. Research Institutes

14. Antithrombin Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Antithrombin Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Antithrombin Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. United States Antithrombin Market

18. China Antithrombin Market

19. Competitive Landscape

  • 19.1. Market Concentration Analysis, 2025
    • 19.1.1. Concentration Ratio (CR)
    • 19.1.2. Herfindahl Hirschman Index (HHI)
  • 19.2. Recent Developments & Impact Analysis, 2025
  • 19.3. Product Portfolio Analysis, 2025
  • 19.4. Benchmarking Analysis, 2025
  • 19.5. Baxter International Inc.
  • 19.6. Bio-Techne Corporation
  • 19.7. Biocon Ltd.
  • 19.8. Boehringer Ingelheim Pharma GmbH & Co. KG
  • 19.9. China Biologic Products, Inc.
  • 19.10. Diapharma Group, Inc.
  • 19.11. European Medicines Agency
  • 19.12. F. Hoffmann-La Roche Ltd
  • 19.13. Genesis BioPharma Services
  • 19.14. Grifols, S.A.
  • 19.15. Jiangsu Hengrui Medicine Co., Ltd.
  • 19.16. Lee Biosolutions, Inc.
  • 19.17. LFB USA, Inc.
  • 19.18. Merck KGaA
  • 19.19. Novartis AG
  • 19.20. Octapharma AG
  • 19.21. Pfizer Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL ANTITHROMBIN MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL ANTITHROMBIN MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL ANTITHROMBIN MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL ANTITHROMBIN MARKET SIZE, BY TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL ANTITHROMBIN MARKET SIZE, BY SOURCE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL ANTITHROMBIN MARKET SIZE, BY FORM, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL ANTITHROMBIN MARKET SIZE, BY DOSAGE FORM, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL ANTITHROMBIN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL ANTITHROMBIN MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ANTITHROMBIN MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL ANTITHROMBIN MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL ANTITHROMBIN MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. UNITED STATES ANTITHROMBIN MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 14. CHINA ANTITHROMBIN MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL ANTITHROMBIN MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL ANTITHROMBIN MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL ANTITHROMBIN MARKET SIZE, BY ALPHA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL ANTITHROMBIN MARKET SIZE, BY ALPHA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL ANTITHROMBIN MARKET SIZE, BY ALPHA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL ANTITHROMBIN MARKET SIZE, BY BETA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL ANTITHROMBIN MARKET SIZE, BY BETA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL ANTITHROMBIN MARKET SIZE, BY BETA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL ANTITHROMBIN MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL ANTITHROMBIN MARKET SIZE, BY HUMAN PLASMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL ANTITHROMBIN MARKET SIZE, BY HUMAN PLASMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL ANTITHROMBIN MARKET SIZE, BY HUMAN PLASMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL ANTITHROMBIN MARKET SIZE, BY RECOMBINANT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL ANTITHROMBIN MARKET SIZE, BY RECOMBINANT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL ANTITHROMBIN MARKET SIZE, BY RECOMBINANT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL ANTITHROMBIN MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL ANTITHROMBIN MARKET SIZE, BY LIQUID, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL ANTITHROMBIN MARKET SIZE, BY LIQUID, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL ANTITHROMBIN MARKET SIZE, BY LIQUID, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL ANTITHROMBIN MARKET SIZE, BY POWDER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL ANTITHROMBIN MARKET SIZE, BY POWDER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL ANTITHROMBIN MARKET SIZE, BY POWDER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL ANTITHROMBIN MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL ANTITHROMBIN MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL ANTITHROMBIN MARKET SIZE, BY INJECTABLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL ANTITHROMBIN MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL ANTITHROMBIN MARKET SIZE, BY ORAL SUSPENSIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL ANTITHROMBIN MARKET SIZE, BY ORAL SUSPENSIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL ANTITHROMBIN MARKET SIZE, BY ORAL SUSPENSIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL ANTITHROMBIN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL ANTITHROMBIN MARKET SIZE, BY ACQUIRED DEFICIENCY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL ANTITHROMBIN MARKET SIZE, BY ACQUIRED DEFICIENCY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL ANTITHROMBIN MARKET SIZE, BY ACQUIRED DEFICIENCY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL ANTITHROMBIN MARKET SIZE, BY ACUTE PANCREATITIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL ANTITHROMBIN MARKET SIZE, BY ACUTE PANCREATITIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL ANTITHROMBIN MARKET SIZE, BY ACUTE PANCREATITIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL ANTITHROMBIN MARKET SIZE, BY CONGENITAL DEFICIENCY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL ANTITHROMBIN MARKET SIZE, BY CONGENITAL DEFICIENCY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL ANTITHROMBIN MARKET SIZE, BY CONGENITAL DEFICIENCY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL ANTITHROMBIN MARKET SIZE, BY DISSEMINATED INTRAVASCULAR COAGULATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL ANTITHROMBIN MARKET SIZE, BY DISSEMINATED INTRAVASCULAR COAGULATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL ANTITHROMBIN MARKET SIZE, BY DISSEMINATED INTRAVASCULAR COAGULATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL ANTITHROMBIN MARKET SIZE, BY LIVER DISEASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL ANTITHROMBIN MARKET SIZE, BY LIVER DISEASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL ANTITHROMBIN MARKET SIZE, BY LIVER DISEASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL ANTITHROMBIN MARKET SIZE, BY SEPSIS ASSOCIATED COAGULOPATHY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL ANTITHROMBIN MARKET SIZE, BY SEPSIS ASSOCIATED COAGULOPATHY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL ANTITHROMBIN MARKET SIZE, BY SEPSIS ASSOCIATED COAGULOPATHY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL ANTITHROMBIN MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL ANTITHROMBIN MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL ANTITHROMBIN MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL ANTITHROMBIN MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL ANTITHROMBIN MARKET SIZE, BY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL ANTITHROMBIN MARKET SIZE, BY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL ANTITHROMBIN MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL ANTITHROMBIN MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL ANTITHROMBIN MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL ANTITHROMBIN MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL ANTITHROMBIN MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL ANTITHROMBIN MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL ANTITHROMBIN MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL ANTITHROMBIN MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL ANTITHROMBIN MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL ANTITHROMBIN MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL ANTITHROMBIN MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. AMERICAS ANTITHROMBIN MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 67. AMERICAS ANTITHROMBIN MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 68. AMERICAS ANTITHROMBIN MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 69. AMERICAS ANTITHROMBIN MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 70. AMERICAS ANTITHROMBIN MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 71. AMERICAS ANTITHROMBIN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 72. AMERICAS ANTITHROMBIN MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 73. NORTH AMERICA ANTITHROMBIN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. NORTH AMERICA ANTITHROMBIN MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 75. NORTH AMERICA ANTITHROMBIN MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 76. NORTH AMERICA ANTITHROMBIN MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 77. NORTH AMERICA ANTITHROMBIN MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 78. NORTH AMERICA ANTITHROMBIN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 79. NORTH AMERICA ANTITHROMBIN MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 80. LATIN AMERICA ANTITHROMBIN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. LATIN AMERICA ANTITHROMBIN MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 82. LATIN AMERICA ANTITHROMBIN MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 83. LATIN AMERICA ANTITHROMBIN MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 84. LATIN AMERICA ANTITHROMBIN MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 85. LATIN AMERICA ANTITHROMBIN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 86. LATIN AMERICA ANTITHROMBIN MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 87. EUROPE, MIDDLE EAST & AFRICA ANTITHROMBIN MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 88. EUROPE, MIDDLE EAST & AFRICA ANTITHROMBIN MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 89. EUROPE, MIDDLE EAST & AFRICA ANTITHROMBIN MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 90. EUROPE, MIDDLE EAST & AFRICA ANTITHROMBIN MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 91. EUROPE, MIDDLE EAST & AFRICA ANTITHROMBIN MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 92. EUROPE, MIDDLE EAST & AFRICA ANTITHROMBIN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 93. EUROPE, MIDDLE EAST & AFRICA ANTITHROMBIN MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 94. EUROPE ANTITHROMBIN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 95. EUROPE ANTITHROMBIN MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 96. EUROPE ANTITHROMBIN MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 97. EUROPE ANTITHROMBIN MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 98. EUROPE ANTITHROMBIN MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 99. EUROPE ANTITHROMBIN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 100. EUROPE ANTITHROMBIN MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 101. MIDDLE EAST ANTITHROMBIN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 102. MIDDLE EAST ANTITHROMBIN MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 103. MIDDLE EAST ANTITHROMBIN MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 104. MIDDLE EAST ANTITHROMBIN MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 105. MIDDLE EAST ANTITHROMBIN MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 106. MIDDLE EAST ANTITHROMBIN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 107. MIDDLE EAST ANTITHROMBIN MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 108. AFRICA ANTITHROMBIN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 109. AFRICA ANTITHROMBIN MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 110. AFRICA ANTITHROMBIN MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 111. AFRICA ANTITHROMBIN MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 112. AFRICA ANTITHROMBIN MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 113. AFRICA ANTITHROMBIN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 114. AFRICA ANTITHROMBIN MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 115. ASIA-PACIFIC ANTITHROMBIN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 116. ASIA-PACIFIC ANTITHROMBIN MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 117. ASIA-PACIFIC ANTITHROMBIN MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 118. ASIA-PACIFIC ANTITHROMBIN MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 119. ASIA-PACIFIC ANTITHROMBIN MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 120. ASIA-PACIFIC ANTITHROMBIN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 121. ASIA-PACIFIC ANTITHROMBIN MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL ANTITHROMBIN MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 123. ASEAN ANTITHROMBIN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 124. ASEAN ANTITHROMBIN MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 125. ASEAN ANTITHROMBIN MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 126. ASEAN ANTITHROMBIN MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 127. ASEAN ANTITHROMBIN MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 128. ASEAN ANTITHROMBIN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 129. ASEAN ANTITHROMBIN MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 130. GCC ANTITHROMBIN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 131. GCC ANTITHROMBIN MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 132. GCC ANTITHROMBIN MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 133. GCC ANTITHROMBIN MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 134. GCC ANTITHROMBIN MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 135. GCC ANTITHROMBIN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 136. GCC ANTITHROMBIN MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 137. EUROPEAN UNION ANTITHROMBIN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 138. EUROPEAN UNION ANTITHROMBIN MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 139. EUROPEAN UNION ANTITHROMBIN MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 140. EUROPEAN UNION ANTITHROMBIN MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 141. EUROPEAN UNION ANTITHROMBIN MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 142. EUROPEAN UNION ANTITHROMBIN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 143. EUROPEAN UNION ANTITHROMBIN MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 144. BRICS ANTITHROMBIN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 145. BRICS ANTITHROMBIN MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 146. BRICS ANTITHROMBIN MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 147. BRICS ANTITHROMBIN MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 148. BRICS ANTITHROMBIN MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 149. BRICS ANTITHROMBIN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 150. BRICS ANTITHROMBIN MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 151. G7 ANTITHROMBIN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 152. G7 ANTITHROMBIN MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 153. G7 ANTITHROMBIN MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 154. G7 ANTITHROMBIN MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 155. G7 ANTITHROMBIN MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 156. G7 ANTITHROMBIN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 157. G7 ANTITHROMBIN MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 158. NATO ANTITHROMBIN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 159. NATO ANTITHROMBIN MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 160. NATO ANTITHROMBIN MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 161. NATO ANTITHROMBIN MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 162. NATO ANTITHROMBIN MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 163. NATO ANTITHROMBIN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 164. NATO ANTITHROMBIN MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 165. GLOBAL ANTITHROMBIN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 166. UNITED STATES ANTITHROMBIN MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 167. UNITED STATES ANTITHROMBIN MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 168. UNITED STATES ANTITHROMBIN MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 169. UNITED STATES ANTITHROMBIN MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 170. UNITED STATES ANTITHROMBIN MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 171. UNITED STATES ANTITHROMBIN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 172. UNITED STATES ANTITHROMBIN MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 173. CHINA ANTITHROMBIN MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 174. CHINA ANTITHROMBIN MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 175. CHINA ANTITHROMBIN MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 176. CHINA ANTITHROMBIN MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 177. CHINA ANTITHROMBIN MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 178. CHINA ANTITHROMBIN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 179. CHINA ANTITHROMBIN MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)